Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified (DBCOND0081492)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT03075553	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Nivolumab	treatment	2	terminated
NCT03278782	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	Pembrolizumab Romidepsin	treatment	1 / 2	active_not_recruiting
NCT04795869	Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma	Brentuximab vedotin Pembrolizumab	treatment	2	withdrawn
NCT03011814	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Durvalumab Lenalidomide	treatment	1 / 2	active_not_recruiting
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT01590732	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Romidepsin	treatment	1	completed
NCT03017820	VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	Cemiplimab Cyclophosphamide Human interferon beta Sodium iodide	treatment	1	recruiting